- Home
- SGHT vs NYXH Comparison
SGHT vs NYXH Comparison
Compare SGHT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- NYXH
- Stock Information
- Founded
- SGHT 2011
- NYXH 2009
- Country
- SGHT United States
- NYXH Belgium
- Employees
- SGHT N/A
- NYXH N/A
- Industry
- SGHT Medical Specialities
- NYXH Medical/Dental Instruments
- Sector
- SGHT Health Care
- NYXH Health Care
- Exchange
- SGHT Nasdaq
- NYXH Nasdaq
- Market Cap
- SGHT 304.4M
- NYXH 261.1M
- IPO Year
- SGHT 2021
- NYXH 2021
- Fundamental
- Price
- SGHT $5.62
- NYXH $9.67
- Analyst Decision
- SGHT Buy
- NYXH Strong Buy
- Analyst Count
- SGHT 6
- NYXH 5
- Target Price
- SGHT $7.20
- NYXH $17.00
- AVG Volume (30 Days)
- SGHT 144.8K
- NYXH 172.4K
- Earning Date
- SGHT 11-07-2024
- NYXH 11-06-2024
- Dividend Yield
- SGHT N/A
- NYXH N/A
- EPS Growth
- SGHT N/A
- NYXH N/A
- EPS
- SGHT N/A
- NYXH N/A
- Revenue
- SGHT $79,395,000.00
- NYXH $5,134,469.00
- Revenue This Year
- SGHT $3.39
- NYXH $49.72
- Revenue Next Year
- SGHT $11.43
- NYXH $395.59
- P/E Ratio
- SGHT N/A
- NYXH N/A
- Revenue Growth
- SGHT N/A
- NYXH 57.79
- 52 Week Low
- SGHT $1.04
- NYXH $4.00
- 52 Week High
- SGHT $8.45
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- SGHT 42.60
- NYXH 65.89
- Support Level
- SGHT $5.74
- NYXH $9.24
- Resistance Level
- SGHT $6.08
- NYXH $9.74
- Average True Range (ATR)
- SGHT 0.31
- NYXH 0.47
- MACD
- SGHT -0.00
- NYXH -0.02
- Stochastic Oscillator
- SGHT 32.58
- NYXH 72.22
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.